Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
7.31
+0.07 (0.97%)
Sep 15, 2025, 4:00 PM EDT - Market closed
Myriad Genetics Revenue
Myriad Genetics had revenue of $213.10M in the quarter ending June 30, 2025, with 0.76% growth. This brings the company's revenue in the last twelve months to $832.90M, up 3.83% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.
Revenue (ttm)
$832.90M
Revenue Growth
+3.83%
P/S Ratio
0.80
Revenue / Employee
$308,481
Employees
2,700
Market Cap
680.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
| Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MYGN News
- 5 days ago - Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 11 days ago - Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology - GlobeNewsWire
- 12 days ago - New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression - GlobeNewsWire
- 19 days ago - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewsWire
- 4 weeks ago - Myriad Genetics Appoints Ben Wheeler Chief Financial Officer - GlobeNewsWire
- 4 weeks ago - New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results - GlobeNewsWire
- 5 weeks ago - Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth - Seeking Alpha
- 5 weeks ago - Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript - Seeking Alpha